Sunitinib fosters marked increase in overall survival in kidney cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 7
Volume 18
Issue 7

Patients with advanced renal cell carcinoma who were treated with sunitinib malate (Sutent) experienced a median overall survival of more than two years, compared with patients who took interferon-alpha, according to Pfizer.

Patients with advanced renal cell carcinoma who were treated with sunitinib malate (Sutent) experienced a median overall survival of more than two years, compared with patients who took interferon-alpha, according to Pfizer.

Results from the phase III trial were published in the Journal of Clinical Oncology. Lead investigator Robert Motzer, MD, and colleagues reported that among 750 patients treated, the overall survival in the sunitinib arm was 26.4 vs 21.8 months in patients who received interferon-alpha (J Clin Oncol online, June 1, 2009).

Patients on sunitinib also had lower severity of disease-related symptoms such as breathlessness and fever, according to a secondary endpoint analysis presented at ASCO 2009 (abstract 6529)

Articles in this issue
Letrozole appears less detrimental than tamoxifen to cognitive function in breast ca
Accelerated whole-breast irradiation does more with less after lumpectomy
RIBBON-1 results bolster bevacizumab as add-on to standard Rx for metastatic breast cancer
PET/CT Indicates if Early Neoadjuvant Rx is Making the Grade in Sarcoma Patients
Less is more when it comes to serial CA125 testing in ovarian cancer
Treatment varies widely in chronic myeloid leukemia
Should expectant management serve as the primary treatment option in prostate cancer?
Oncology takes blame for rising healthcare cost
Healthcare advocates call for universal coverage, acknowledge challenges
NSABP chair admits ‘failure’ in C-08 trial, denies defeat
Gemcitabine, capecitabine regimens equal in breast ca mets
Study ties survival to inflammatory markers in breast cancer
Canadians rally for national standards for breast ca testing
Trio of genes plays role in breast ca mets to brain
Micromet BiTE antibody eliminates leukemia cells
Related Videos
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Related Content
Pembrolizumab also demonstrated a disease-free survival benefit vs placebo for patients with clear-cell renal cell carcinoma.

Pembrolizumab Prolongs Survival in Clear-Cell RCC

April 18th 2024
Article

Pembrolizumab also demonstrated a disease-free survival benefit vs placebo for patients with clear-cell renal cell carcinoma.

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Finding Ways to Break the Mold in GU Oncology

April 8th 2024
Podcast

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Mary-Ellen Taplin, MD, gives her advice on how to achieve work-life balance and make other career advancements in genitourinary cancer.

Taplin’s Key to a Successful GU Career: “Always Finish” What You Start

March 28th 2024
Article

Mary-Ellen Taplin, MD, gives her advice on how to achieve work-life balance and make other career advancements in genitourinary cancer.

Santosh Rao, MD, discusses the formation of new guidelines informing the use of integrative oncology for patients with kidney cancer from the Society for Integrative Oncology.

Oncology On-The-Go Podcast: Integrative and Palliative Kidney Cancer Care

March 28th 2023
Podcast

Santosh Rao, MD, discusses the formation of new guidelines informing the use of integrative oncology for patients with kidney cancer from the Society for Integrative Oncology.

Practices should not differentiate treatment options based on race for patients with metastatic renal cell carcinoma, according to Jasmeet Kaur, MD.

Comparable Findings in White and Black Populations for ICI Use in Metastatic RCC

February 20th 2024
Article

Practices should not differentiate treatment options based on race for patients with metastatic renal cell carcinoma, according to Jasmeet Kaur, MD.

Interim findings from a phase 3 trial support adjuvant pembrolizumab as a new therapeutic option for those with muscle-invasive urothelial carcinoma at high risk of recurrence.

Pembrolizumab Improves DFS Vs Observation in Muscle-Invasive Urothelial Carcinoma

February 8th 2024
Article

Interim findings from a phase 3 trial support adjuvant pembrolizumab as a new therapeutic option for those with muscle-invasive urothelial carcinoma at high risk of recurrence.